Cutting edge Finometer equipment introduced

July 2004


The newest addition to our sophisticated range of technologies is the highly accurate and reliable blood pressure measuring device, the Finometer.Our Research Director, Dr Radivoj Arezina, MD MSc, commented “Our new Finometer compliments our expanding range of highly sophisticated equipment. The device not only allows continuous measurement of blood pressure in a particularly thorough and scientific manner, but also stores information and converts it into a range of user friendly formats to enable accurate analysis of the waveform. The impact this type of technology has on clinical studies is considerable; we now provide rapid, wide ranging and definitive analysis on the effect of drugs on arterial blood pressure.”The instrument includes Beatscope PC-based software and allows almost complete non-invasive characterisation of the arterial circulation and its beat-to-beat variability in pressure and flow. The new device is able to measure systolic, diastolic and true mean arterial pressure, heart rate, interbeat interval, left ventricular ejection time, stroke volume, cardiac output, systemic peripheral resistance and a time-tension index.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more